Stoke Therapeutics (STOK) Capital Expenditures (2018 - 2026)
Stoke Therapeutics (STOK) posted quarterly Capital Expenditures of $353000.0 for Q1 2026, up 1207.41% year-over-year from $27000.0 in Q1 2025, and down 38.93% quarter-over-quarter from $578000.0 in Q4 2025.
Stoke Therapeutics (STOK) Capital Expenditures (2018 - 2026) Analysis & Trends
Stoke Therapeutics' Capital Expenditures history runs 9 years deep, the most recent figure standing at $353000.0 for Q1 2026.
- In Q1 2026, Capital Expenditures rose 1207.41% year-over-year to $353000.0; the TTM figure through Mar 2026 stood at $996000.0 (up 344.64% YoY), while the FY2025 annual figure was $670000.0, up 230.05% from the prior year.
- Capital Expenditures for Q1 2026 stood at $353000.0, down from $578000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $841000.0 in Q1 2022, with the low at -$348000.0 in Q3 2022.
- The 5-year median for Capital Expenditures is $52000.0 (2024), against an average of $174294.1.
- The sharpest annual moves came in 2022 and 2026: Capital Expenditures sank 227.47% in 2022, then soared 1207.41% in 2026.
- Stoke Therapeutics' Capital Expenditures stood at -$285000.0 in 2022, then soared by 180.35% to $229000.0 in 2023, then fell by 16.16% to $192000.0 in 2024, then soared by 201.04% to $578000.0 in 2025, then sank by 38.93% to $353000.0 in 2026.
- Business Quant data shows STOK's Capital Expenditures at $353000.0 in Q1 2026, $578000.0 in Q4 2025, and $41000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Stoke Therapeutics | 1.95 Bn | 1.66 Bn | - | 1.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.98 Mn |
| Jun 30, 2026 | 1.98 Mn |
| Mar 31, 2026 | 353,000.00 |
| Mar 31, 2026 | 353,000.00 |
| Dec 31, 2025 | 578,000.00 |
| Dec 31, 2025 | 578,000.00 |
| Sep 30, 2025 | 41,000.00 |
| Sep 30, 2025 | 41,000.00 |
| Jun 30, 2025 | 24,000.00 |
| Jun 30, 2025 | 24,000.00 |
| Mar 31, 2025 | 27,000.00 |
| Mar 31, 2025 | 27,000.00 |
| Dec 31, 2024 | 192,000.00 |
| Dec 31, 2024 | 192,000.00 |
| Sep 30, 2024 | -47,000.00 |
| Sep 30, 2024 | -47,000.00 |
| Jun 30, 2024 | 52,000.00 |
| Jun 30, 2024 | 52,000.00 |
| Mar 31, 2024 | 6,000.00 |
| Mar 31, 2024 | 6,000.00 |